Medivis
+61%
est. 2Y upside i
Medivis uses technological advancements in augmented reality and computer vision to create a holographic future for surgery.
Rank
#809
Sector
Healthtech
Est. Liquidity
~2Y
Data Quality
Data: LowMedivis offers potential upside of ~61% probability-weighted over 2 years, driven by a novel FDA-cleared AR platform.
Last updated: July 19, 2026
Medivis achieves rapid adoption of its FDA-cleared Spine Navigation, expanding to cranial applications; exit multiple holds at 12x on projected $18.1M revenue, yielding a market cap of $218M.
Revenue grows to $18.1M with moderate market penetration; exit multiple settles at 8x, in line with public medtech comps, yielding $145M valuation.
Adoption lags due to incumbent competition and slow hospital procurement; multiple compresses to 4x, yielding $73M exit, below entry valuation.
Preference Stack Risk
highFunding Intensity
28%$22.3M in preferred stock, representing 27.9% of entry valuation.
Dilution Risk
highExpected additional funding rounds within 2 years, likely diluting common equity by ~20%.
Secondary Liquidity
noneNo secondary market activity observed.
Questions to Ask at the Interview
Strategic questions based on Medivis's data — designed to show you've done your homework.
- 1
“How does Medivis plan to scale FDA clearances beyond spine and cranial?”
- 2
“What is the sales cycle and average contract value for hospital deployments?”
- 3
“How does the equity structure (preferred vs common) impact employee outcomes in a liquidity event?”
Community
Valuation Sentiment
Our model estimates +61% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.